Breakthrough Alzheimer’s Drugs Unlikely to Benefit Patients, Report Suggests

A recent analysis challenges the effectiveness of newly hailed Alzheimer’s treatments, claiming they may not offer substantial benefits to patients. The study, conducted by the Cochrane Collaboration, found that while these drugs slow cognitive decline, the effect is insufficient to meaningfully improve dementia care. The research evaluated 17 studies involving 20,342 participants, focusing on medications that remove beta amyloid—a protein associated with brain cell damage—in Alzheimer’s disease.

These drugs, which use antibodies to target amyloid plaques, have shown promise in recent trials, such as those for donanemab and lecanemab. However, the Cochrane team argues that the overall impact remains “well below” what is required to make a significant difference for patients. The findings have sparked strong disagreement from other scientists, who call the analysis “fundamentally flawed” and question its conclusion.

One of the report’s contributors, Prof Edo Richard of Radboud University Medical Centre, emphasized the need for transparency. “I would tell patients they might not gain much from these drugs, and the treatment could be a burden for families,” he said in a

interview. “It’s vital to avoid giving false hope without clear evidence of real benefits.”

He also noted that alternative strategies, like addressing brain inflammation, deserve further investigation.

Meanwhile, Prof Robert Howard from University College London criticized the report for undermining decades of research. “Hyping these drugs without solid science has led to misplaced optimism,” he stated in a

statement. “Families deserve honest discussions about what these treatments truly offer.”

The report’s methodology, which grouped all amyloid-targeting drugs together, has been disputed. Prof Bart De Strooper of the UK Dementia Research Institute called it “a fundamental flaw,” highlighting that newer antibodies have demonstrated measurable, though modest, clinical value.

Despite the debate, the high cost of these drugs remains a barrier. An 18-month course would cost £90,000 privately, making them unaffordable for most. In the UK, NHS coverage is pending, with the National Institute for Health and Care Excellence reassessing the evidence to consider the impact on unpaid caregivers.

While the Cochrane report questions the drugs’ efficacy, their ability to reduce amyloid buildup marks a critical step in Alzheimer’s research. The ongoing discussion underscores the tension between innovation and evidence, as scientists weigh the potential of these therapies against their limitations.